The disclosure relates to the technical field of virus detection, in particular, to an IgA antibody and a kit capable of specifically recognizing RBD protein. The antibody can be used as a calibrator of IgA antibody against the RBD protein of SARS-CoV-2. the disclosure further relates to a kit comprising the antibody which enables automated, high-throughput, and rapid detection of IgA antibody against novel coronavirus pneumonia

Provided herein is a test system comprising severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen, SARS-CoV-2 S2 antigen, and binding moieties that specifically bind to human IgG, human IgA, and human IgM. Also provided are methods of detecting SARS-CoV-2 antibodies in a sample using the test system.

Mycobacterial antigens, such as MAP and M. bovis antigens, are described. The antigens can be used in subunit compositions to elicit immune responses in order to prevent and/or control mycobacterial infections, as well as in diagnostics in order to detect mammals infected with mycobacteria.

Disclosed herein is a method of detecting the presence of a target analyte in a sample. Disclosed herein are also a system, an article, and a kit for detecting the presence of a target analyte in a sample. Disclosed herein is also the use of the system, or the article, or the kit for biomolecule, bioorganelle, bioparticle, cell and microorganism detection.

Provided are dosing regimens of polyomavirus neutralizing antibodies and related methods and pharmaceutical compositions for treating polyomavirus infections.

Disclosed are neoglycoconjugates and/or glycosides containing glycan selected from Galpα1,3Galfβ, Galpα1,6Galpα1,3Galfβ, or Galpα1,3Galfβ1,3Manpα. Methods of using the glycosides and/or neoglycoconjugates as diagnostic or prognostic biomarkers, vaccines, treating or detecting parasitic diseases, such as cutaneous leishmaniasis are disclosed.

Lateral flow immunoassays that reliably detect human antibodies, including IgG and/or IgM antibodies, specific for severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) are described herein. Devices, methods and kits for analysis of samples, such as liquid blood, serum or plasma, for the presence of human antibodies, such as IgG and/or IgM antibodies, specific for SARS CoV-2 proteins, such as SARS CoV-2 N and/or S proteins are provided.

Methods, systems and devices for determining COVID disease, including receiving symptom data values, calculating first differentials (positive or negative) for the first virus strain by comparing the values to first predetermined symptom threshold values for the first virus strain, using the first differentials to detect a second virus strain with a mutated virus genome code based on a correspondence of its symptoms to the first differentials, calculating second differentials (positive or negative) for the second virus strain by comparing the values to second predetermined symptom threshold values for the second virus strain, creating a superset of the first and second differentials, detecting correlations within the superset, determining that the person has the first or second virus strain when at least one detected correlation indicates that the person has contracted the first or second virus strain, outputting a result indicating a presence or absence of COVID in a person.

Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.

Described herein are compositions that comprise one or more Babesia microti antigens, one or more Babesia microti nucleic acid molecules, or one or more anti-Babesia microti antibodies and uses thereof in methods for the prophylaxis of babesiosis, the treatment of babesiosis and the monitoring of individuals undergoing prophylactic or therapeutic administration of the compositions of the invention.